ADT in High-Risk Prostate Cancer: How to Advise Patients?

Dr. Gerald Chodak interprets findings from a new study comparing 18-month vs 36-month hormone therapy in high-risk prostate cancer patients.

Source: Medscape Urology Podcast - March 4, 2013 Category: Urology & Nephrology Authors: Medscape Source Type: podcasts